Background
==========

World Health Organization position paper on immunotherapy recommends using mite allergen vaccines for rhinitis and mild to moderate asthma. Allergic sensitization to domestic mites and particularly to *Dermatophagoides pteronyssinus*, *Dermatophagoides siboney* and *Blomia tropicalis* has been described before in Cuba, as strongly linked to respiratory allergy symptoms. The aim of this work was to study the therapeutic effect and safety of allergen vaccines of these 3 mite species (VALERGEN, BIOCEN, Cuba) by subcutaneous route, in asthmatic patients.

Methods
=======

Three Double-Blind Placebo-Controlled clinical trials were performed in 40 patients each, showing asthmatic symptoms and positive predominant Skin Prick Test (SPT) to each mite, respectively. Half of patients received the active treatment consisting of subcutaneous injections with increasing doses, up to 6000 BU. Therapeutic effect was assessed after 6 and 12 months using symptoms/medication diary cards, peak expiratory flow (PEF) measures and skin sensitivity to investigated mites. Adverse reactions were classified using the World Allergy Organization scale.

Results
=======

The total 1 year cumulative dose was 63035 BU, in an average of 20.5 injections. The treatment was effective in the reduction of clinical symptoms (up to 32%, 95%CI:28-36%; p=0.0006) and medication intake (23%, 95%CI:18-28%), as compared to control treatment. The skin sensitivity to the allergens decreased significantly (p=0.0001), with regard to the beginning of the treatment. The allergen amount needed to induce a positive SPT increased 297-fold. Improvement of the lung function was observed, expressed in a modest Peak-Expiratory-Flow increase (p\<0.05) and reduction of PEF daily variability. SIT was considered effective in 71% of patients. The frequency of local adverse reactions was 2.4 % of injections.

Conclusions
===========

Summing up subcutaneous immunotherapy, using VALERGEN vaccines, is effective and safe for the control and amelioration of the asthma.
